한글목차

아토피 피부염 치료제 시장 규모는 2025년 87억 7,000만 달러에서 2034년에는 162억 달러에 달할 것으로 예측되고 있으며, 2026-2034년에 CAGR 7.06%로 성장할 전망입니다.

아토피피부염은 만성 염증성 피부질환으로 유병률이 지속적으로 증가하고 있으며, 아토피피부염 치료제 시장은 큰 폭의 성장이 예상되고 있습니다. 아토피 피부염은 건조, 가려움증, 염증이 특징이며, 환자의 삶의 질에 큰 영향을 미칩니다. 이 질환과 그 관리에 대한 인식이 높아지면서 효과적인 치료법에 대한 수요가 증가하고 있습니다. 아토피 피부염 치료제 시장은 의료진이 환자의 치료 결과를 개선하고 증상 부담을 줄이기 위해 노력하면서 지속적으로 성장할 것으로 예측됩니다.

기술 발전은 아토피 피부염 치료제 시장 전망를 형성하는 데 중요한 역할을 하고 있습니다. 코르티코스테로이드와 비스테로이드성 항염증약를 포함한 외용제 치료의 혁신으로 증상 악화시 관리와 장기적인 조절이 개선되고 있습니다. 또한 염증에 관여하는 특정 경로를 표적으로 하는 생물학적 치료제의 개발도 주목받고 있습니다. 제약회사들이 연구개발과 임상시험에 대한 투자를 지속하고 있는 가운데, 유효성과 안전성 프로파일이 개선된 새로운 치료법의 채택이 시장에서 증가할 것으로 예측됩니다.

또한 맞춤형 의료와 환자 중심의 치료에 대한 관심이 높아지면서 아토피피부염 치료제 시장의 성장 궤도에 영향을 미치고 있습니다. 환자들이 치료 계획에 더 많이 참여함에 따라 개인의 필요와 선호에 따른 치료법에 대한 수요가 증가하고 있습니다. 이러한 추세에 따라 의료진, 연구자, 환자가 협력하여 치료 지속률과 만족도를 높이는 맞춤형 치료 전략을 개발하고 있습니다. 시장이 계속 진화하는 가운데, 기술 도입, 개별화 접근, 환자 교육의 통합이 성공의 열쇠가 될 것입니다.

목차

제1장 서론

제2장 개요

제3장 시장 변수, 동향, 프레임워크

제4장 세계의 아토피 피부염 치료제 시장 : 약제 유형별

제5장 세계의 아토피 피부염 치료제 시장 : 용도별

제6장 세계의 아토피 피부염 치료제 시장 : 유통 채널별

제7장 세계의 아토피 피부염 치료제 시장 : 지역별

제8장 경쟁 구도

제9장 기업 개요

영문목차

The Atopic Dermatitis Drugs Market size is expected to reach USD 16.20 Billion in 2034 from USD 8.77 Billion (2025) growing at a CAGR of 7.06% during 2026-2034.

The Atopic Dermatitis Drugs Market is poised for significant growth as the prevalence of atopic dermatitis, a chronic inflammatory skin condition, continues to rise. Atopic dermatitis is characterized by dry, itchy, and inflamed skin, significantly impacting patients' quality of life. The increasing awareness of the condition and its management is driving the demand for effective therapeutic options. As healthcare providers seek to improve patient outcomes and reduce the burden of symptoms, the market for atopic dermatitis drugs is expected to flourish.

Technological advancements are playing a crucial role in shaping the future of the atopic dermatitis drugs market. Innovations in topical treatments, including corticosteroids and non-steroidal anti-inflammatory drugs, are enhancing the management of flare-ups and long-term control. Additionally, the development of biologic therapies targeting specific pathways involved in inflammation is gaining traction. As pharmaceutical companies continue to invest in research and clinical trials, the market is likely to see increased adoption of novel therapies that offer improved efficacy and safety profiles.

Moreover, the growing emphasis on personalized medicine and patient-centered care is influencing the atopic dermatitis drugs market's growth trajectory. As patients become more engaged in their treatment plans, there is a rising demand for therapies that cater to individual needs and preferences. This trend is driving collaboration between healthcare providers, researchers, and patients to develop tailored treatment strategies that enhance adherence and satisfaction. As the market continues to evolve, the integration of technology, personalized approaches, and patient education will be key drivers of success.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• BCR-ABL Atopic Dermatitis Drugs
• Corticosteroids
• Calcineurin Inhibitors
• PDE4 Inhibitors
• Biologics
• Others

By Application

• Topical
• Parenteral
• Oral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Pfizer Inc, Sanofi, AbbVie Inc, Galderma Laboratories, LP, Eli Lilly and Company Dermira, Regeneron Pharmaceuticals Inc, LEO Pharma Inc, Otsuka Pharmaceutical Co, Ltd, Novartis AG, Incyte Corporation

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ATOPIC DERMATITIS DRUGS MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. BCR-ABL Atopic Dermatitis Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Calcineurin Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. PDE4 Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Biologics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ATOPIC DERMATITIS DRUGS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ATOPIC DERMATITIS DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ATOPIC DERMATITIS DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Type
  • 7.2.2 By Application
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Type
  • 7.3.2 By Application
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Type
  • 7.4.2 By Application
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Type
  • 7.5.2 By Application
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Type
  • 7.6.2 By Application
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ATOPIC DERMATITIS DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Pfizer Inc
  • 9.2.2 Sanofi
  • 9.2.3 AbbVie Inc
  • 9.2.4 Galderma Laboratories, L.P
  • 9.2.5 Eli Lilly And Company (Dermira)
  • 9.2.6 Regeneron Pharmaceuticals Inc
  • 9.2.7 LEO Pharma Inc
  • 9.2.8 Otsuka Pharmaceutical Co.Ltd
  • 9.2.9 Novartis AG
  • 9.2.10 Incyte Corporation